Liquidia (NASDAQ:LQDA) Rating Increased to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA) to a strong-buy rating in a research note published on Wednesday, Zacks.com reports.

Several other equities analysts have also recently issued reports on the stock. Needham & Company LLC restated a buy rating and issued a $25.00 price target on shares of Liquidia in a research report on Monday, August 19th. Bank of America decreased their price target on shares of Liquidia from $24.00 to $23.00 and set a buy rating for the company in a research report on Tuesday, August 20th. BTIG Research decreased their price target on shares of Liquidia from $29.00 to $25.00 and set a buy rating for the company in a research report on Monday, August 19th. Raymond James upgraded shares of Liquidia from an outperform rating to a strong-buy rating in a research report on Monday, August 19th. Finally, Oppenheimer started coverage on shares of Liquidia in a research report on Tuesday, June 25th. They set a market perform rating for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $24.00.

Liquidia Price Performance

LQDA stock opened at $10.03 on Wednesday. The company has a 50 day simple moving average of $10.44 and a 200 day simple moving average of $12.24. The stock has a market cap of $766.43 million, a price-to-earnings ratio of -6.43 and a beta of 0.22. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. On average, equities research analysts anticipate that Liquidia will post -1.71 EPS for the current fiscal year.

Insider Transactions at Liquidia

In related news, Director Caligan Partners Lp bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were acquired at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Caligan Partners Lp bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were acquired at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the transaction, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,422 shares of company stock worth $256,998 over the last three months. 31.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Patient Square Capital LP bought a new position in shares of Liquidia in the first quarter valued at $105,942,000. Vanguard Group Inc. lifted its stake in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after buying an additional 43,352 shares in the last quarter. Kynam Capital Management LP lifted its stake in shares of Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after buying an additional 698,324 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Liquidia in the first quarter valued at $30,311,000. Finally, Vestal Point Capital LP bought a new position in shares of Liquidia in the fourth quarter valued at $12,331,000. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).